Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 609 clinical trials
featured
Platinum-Resistant Ovarian Cancer

A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208) Women with platinum resistant ovarian cancer are

platinum-resistant ovarian cancer
  • 60 views
  • 18 Feb, 2020
  • 1 location
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based

  • 1940 views
  • 25 Mar, 2021
  • 107 locations
featured
Ovarian Cancer (OVATION 2)

People with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer are asked to participate in a research study being conducted by Northwell Health.  

fallopian tube
peritoneal cancer
  • 37 views
  • 18 Feb, 2020
  • 1 location
featured
Advanced Ovarian Cancer

Advanced Ovarian Cancer

  • 116 views
  • 08 Nov, 2020
  • 1 location
featured
EpicentRx RRx001-211-01: RRx-001 in Patients with Small Cell Lung Cancer, High-grade Neuroendocrine Carcinoma, EGFR Mutation Positive Non-Small Cell Lung Cancer or Ovarian Cancer (Including Malignant Mixed Mullerian Tumore (MMMT) of the Ovary or Uterus) Previously Treated with a Platinum-based Regimen (QUADRUPLE THREAT)

EpicentRx RRx001-211-01: RRx-001 in Patients with Small Cell Lung Cancer, High-grade Neuroendocrine Carcinoma, EGFR Mutation Positive Non-Small Cell Lung Cancer or Ovarian Cancer (Including

ovarian cancer
carcinoma
cancer
small cell carcinoma
lung carcinoma
  • 786 views
  • 24 Nov, 2020
  • 1 location
featured
Ovarian, Fallopian Tube or Peritoneal Cancer

Ovarian, Fallopian Tube or Peritoneal Cancer

  • 616 views
  • 08 Nov, 2020
  • 1 location
featured
GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

  • 524 views
  • 08 Nov, 2020
  • 1 location
featured
GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary

GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary

  • 544 views
  • 08 Nov, 2020
  • 1 location
featured
A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • 644 views
  • 08 Nov, 2020
  • 5 locations
featured
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.  This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose …

ovarian cancer
urothelial carcinoma
metastatic cervical cancer
carcinoma
  • 156 views
  • 23 Nov, 2020
  • 4 locations